Objective-Macrophages play key roles in inflammation and diabetic vascular complications. Emerging evidence implicates long noncoding RNAs in inflammation, but their role in macrophage dysfunction associated with inflammatory diabetic complications is unclear and was therefore investigated in this study. Approach and Results-RNA-sequencing and real-time quantitative PCR demonstrated that a long noncoding RNA Dnm3os (dynamin 3 opposite strand) is upregulated in bone marrow-derived macrophages from type 2 diabetic db/db mice, dietinduced insulin-resistant mice, and diabetic ApoE −/− mice, as well as in monocytes from type 2 diabetic patients relative to controls. Diabetic conditions (high glucose and palmitic acid) induced Dnm3os in mouse and human macrophages. Promoter reporter analysis and chromatin immunoprecipitation assays demonstrated that diabetic conditions induce Dnm3os via NF-κB activation. RNA fluorescence in situ hybridization and real-time quantitative PCRs of subcellular fractions demonstrated nuclear localization and chromatin enrichment of Dnm3os in macrophages. Stable overexpression of Dnm3os in macrophages altered global histone modifications and upregulated inflammation and immune response genes and phagocytosis. Conversely, RNAi-mediated knockdown of Dnm3os attenuated these responses. RNA pull-down assays with macrophage nuclear lysates identified nucleolin and ILF-2 (interleukin enhancer-binding factor 2) as protein binding partners of Dnm3os, which was further confirmed by RNA fluorescence in situ hybridization immunofluorescence. Furthermore, nucleolin levels were decreased in diabetic conditions, and its knockdown enhanced Dnm3os-induced inflammatory gene expression and histone H3K9-acetylation at their promoters.
M etabolic syndrome and diabetes mellitus are associated with insulin resistance, hyperglycemia, and hyperlipidemia that contribute to chronic inflammation implicated in the pathogenesis of vascular complications such as atherosclerosis. [1] [2] [3] Monocyte recruitment into target tissues and differentiation into macrophages are key processes in inflammation associated with such complications. Diabetes mellitus accelerates these vascular complications by skewing monocyte/macrophage polarization, proliferation and dysfunction to enhance inflammation, foam cell formation, and promote defective apoptosis and efferocytosis. [2] [3] [4] [5] These adverse proinflammatory effects of diabetes mellitus and insulin resistance on macrophages can be mediated by high glucose (HG), advanced glycation end products, elevated free fatty acids such as palmitic acid (PA) and oxidized lipids. 2, 3, 6, 7 Several studies demonstrated the role of oxidative stress, activation of the receptor for advanced glycation end products, signaling pathways including protein kinase C, and transcription factors (TF) such as NF-κB. 8, 9 Epigenetic mechanisms, including promoter histone H3 lysine 9/14 acetylation (H3K9ac) and H3K4 methylation have also been implicated in inflammatory gene regulation associated with diabetic complications. 10 However, much less is known about the role of noncoding RNAs like long noncoding RNAs (lncRNAs) in regulating genes and processes associated with inflammation and macrophage dysfunction in diabetes mellitus.
Emerging evidence shows lncRNAs are involved in diverse biological processes such as cell proliferation and differentiation. 11, 12 LncRNAs are longer than 200 bp, lack coding potential and are expressed from intergenic regions or introns, as antisense to coding transcripts, pseudogenes, host genes of microRNAs, and from enhancers. [11] [12] [13] [14] LncRNA actions include transcription regulation via directing epigenetic factors such as polycomb repressive complexes to chromatin, acting as scaffolds for chromatin remodeling proteins and TFs and regulation of mRNA stability/translation, and inhibition of microRNA functions. [11] [12] [13] 15 Changes in lncRNA expression can dysregulate key functions of cardiac, vascular, and renal cells implicated in diabetic vascular complications and cardiovascular diseases. 14, [16] [17] [18] [19] Recent studies have identified several lncRNAs expressed in macrophages and monocytes that mediate pro-and anti-inflammatory processes, cell differentiation, and survival. 20 These macrophage lncRNAs act through diverse mechanisms including regulation of proinflammatory TFs like NF-κB, interaction with hnRNPs (heterogeneous nuclear ribonulceo proteins) and epigenetic regulators such as polycomb repressive complexes to promote chromatin remodeling at target gene promoters. [20] [21] [22] [23] However, these aspects of lncRNA functions have not been studied in diabetes mellitus-induced macrophage dysfunction.
We recently demonstrated that bone marrow-derived macrophages (BMDMs) obtained from obese, type 2 diabetic (T2D) db/db mice exhibited enhanced inflammatory genes, and dysregulation of genes associated with macrophage alternate activation compared with BMDMs from control nondiabetic db/+ mice. Interestingly, these transcriptome changes were also associated with altered expression of several lncRNAs. One of the upregulated lncRNAs, E330013P06 was found to promote proinflammatory and proatherogenic phenotype in macrophages. 24 However, the regulation and function of other differentially expressed lncRNAs in diabetic macrophages are not known. Here, we demonstrate that a lncRNA Dnm3os (dynamin 3 opposite strand) is upregulated in macrophages and monocytes under diabetic conditions via NF-κB activation. Furthermore, we found Dnm3os interacts with nucleolin, a nuclear protein, in macrophages, and that disruption of Dnm3os-nucleolin interactions under diabetic conditions can enhance inflammatory gene expression via epigenetic mechanisms. The results illustrate novel mechanisms underlying lncRNA-dependent regulation of macrophage inflammation in diabetes mellitus.
Materials and Methods
The authors declare that all supporting data are available within the article (and its online supplementary files).
Isolation of BMDMs and Peritoneal Macrophages From Mice
Animal experiments were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee. BMDMs were prepared from 10 to 12-week-old T2D male and female db/db mice and control db/+ littermates, and male C57BL/6 mice (Jackson Laboratories, Maine) as described. 24 Bone marrow cells were obtained from femurs and tibia and differentiated into macrophages for 7 to 8 days in macrophage complete medium containing DMEM (Cat. No. 12-707F, Lonza, Basel, Switzerland) with 5.5 mmol/L glucose, 10% heat inactivated fetal bovine serum (Cat. No. S11150, Atlanta Biologicals, Flowery Branch, GA), 2 mmol/L glutamine, penicillin/ streptomycin (100 μmol/L), 50 μmol/L β-mercaptoethanol, and 10 mmol/L HEPES, pH 7.4 supplemented with 20 ng/mL of M-CSF (Cat. No. 416-ML-050, R&D Systems, Minneapolis, MN). Thioglycollateelicited peritoneal macrophages (PMs) were isolated from control C57BL/6 and streptozotocin (STZ) injected (50 mg/kg per day for 5 days) type 1 diabetic mice as well as C57BL/6 mice (8 weeks old) fed high-fat diet (60% kcal, Research Diets Inc, D12492i) or normal chow diet for 8 weeks as described. 24 In addition, male Apoe −/− mice (Jackson Laboratory, stock number 002052) were injected with STZ (50 mg/kg per day) or citrate buffer for 5 consecutive days. BMDMs were prepared at 20 weeks postdiabetes mellitus (>500 mg/dL of glucose versus 160 mg/dL in controls) when diabetic Apoe −/− mice exhibited accelerated atherosclerosis. Mouse macrophage cell line RAW264.7 (ATCC, Manassas, VA) was maintained in macrophage complete medium. Where indicated, macrophages were treated with media containing 200 μmol/L PA (Nu-Check Prep, Inc, MN) or control BSA for indicated periods. PA stock solutions (10 mmol/L) were freshly prepared in BSA, diluted to the indicated concentration in macrophage complete medium, incubated for 30 minutes at 37°C, and filtered with 0.2 μm filter before treating macrophages and monocytes. 24 
Isolation of Primary Human Monocytes and Human Macrophages
Human monocyte experiments were performed in accordance with approved protocols from the Baylor College of Medicine and the City of Hope Medical Center. After informed consent CD14+ monocytes were obtained from T2D patients and healthy controls (age and sex matched) at the Baylor College of Medicine. Patient data and monocyte isolation methods have been described. 24 In some experiments, CD14+ monocytes from healthy donors (All Cells, Emeryville, CA) and THP1 monocytes (ATCC TIB-202) were differentiated into macrophages using MCSF (50 ng/mL) for 1 week and PMA (20 ng/mL, up to 48 hours), respectively. 
RNA Isolation and Gene Expression

Transfection of Macrophages
RAW macrophages were transfected with indicated siRNAs, expression vectors or promoter reporter plasmids using Nucleofection kit (Lonza, Gaithersburg, MD) for macrophages (program Y-001) 24, 25 or RNAiMAX (Cat. No. 13778-150, Thermo Fisher Scientific) according to manufacturer's protocols. THP1 macrophages were transfected with indicated GapmeRs (50 nmol/L) using RNAiMAX. Transfected cells were processed for RNA extraction, phagocytosis assays, luciferase assays, and chromatin immunoprecipitation (ChIP) assays as indicated at 48 to 72 hours posttransfection.
RAW Macrophage Cell Lines Stably Overexpressing Dnm3os
We generated Dnm3os expression vector (pDnm3os) by cloning Dnm3os (7.928 kb) into pcDNA 3.1 (+) (Thermo Fisher) and verified by DNA sequencing. RAW264.7 macrophages were transfected with pDnm3os or pcDNA3.1(+) empty vector (EV) using nucleofection. Single cells clones stably expressing Dnm3os (RAW-Dnm3os) and EV (RAW-EV) were selected by Geneticin (Cat. No. 10131027, Thermo Fisher Scientific, 500 μg/mL).
Cloning of Dnm3os Promoter and Luciferase Assays
Mouse genomic DNA fragments (1250 and 731 bp containing Dnm3os promoter (−1000 and −500 bp upstream from TSS) were cloned into SacI-XhoI sites of the pGL4.10[luc2] (Promega, Madison, WI) upstream of firefly luciferase and verified by DNA sequencing. RAW264.7 cells were cotransfected with Dnm3os reporters and pRL-TK expressing Renilla luciferase (internal control) using nucleofection. Next day treated ±PA (6 hours) or HG (24 hours 
Subcellular Fractionation of Macrophages
RNA from nuclear and cytoplasmic fractions of RAW macrophages and db/db mice BMDMs were prepared using Nuclear and cytoplasmic RNA purification kit (Cat. No. 21000, Norgen, ON, Canada) following manufacturer's protocols. Chromatin from RAW macrophages was isolated following published methods. 26 RAW264.7 cells (80% confluent) were detached by Accutase and 2×10 7 cells were lysed with equal volumes of Buffer A (10 mmol/L HEPES pH 7.5, 10 mmol/L KCl, 10% glycerol, 340 mmol/L sucrose, 4 mmol/L MgCl2, 1 mmol/L DTT, and 1x Complete protease inhibitor (Cat. No. 11697498001, Sigma) containing 0.2% Triton X-100 (12 minutes on ice). Lysates were centrifuged at 1200g, 5 minutes, 4°C, and supernatants were saved as cytoplasmic fractions. The nuclear pellets were washed once (500g for 5 minutes at 4°C) with 250 µL of NRB (20 mmol/L HEPES pH 7.5, 50% Glycerol, 75 mmol/L NaCl, 1 mmol/L DTT, and 1x Complete protease inhibitor), resuspended in 250 µL NRB and mixed with an equal volume of NUN buffer (20 mmol/L HEPES, 300 mmol/L NaCl, 1 mol/L Urea, 1% NP40, 10 mmol/L MgCl 2 , and 1 mmol/L DTT). After incubation for 5 minutes on ice, centrifuged (1200g, 5 minutes, 4°C) and soluble nuclear supernatant (SNE) was transferred to another tube. The depleted nuclear pellet was washed once with 1 mL buffer A and chromatin-enriched pellet was resuspended in 50 µL buffer A. RNA was isolated from SNE and chromatin-enriched fractions using Trizol (Cat. No. 15596026, Thermo Fisher Scientific) and RNeasy mini kit.
Western Blotting
Whole cell protein lysates and Western blotting were performed as described. 27 Western blots were probed with indicated primary antibodies for 24 hours at 4°C, washed, and incubated with HRPconjugated anti-rabbit (Cat. No. AP307P, Millipore, Darmstadt, Germany, 0.33 μg/mL) or antimouse (Cat. No. 1706516, Biorad Hercules, CA, 0.07 μg/mL) secondary antibodies for 1 hour at room temperature. Blots were washed and protein bands visualized using chemiluminescence detection. Antibodies against Histone H3 (ab1791), H3K27ac (ab4729), H3K9ac (ab4441), and nucleolin (ab22758) were from Abcam, Cambridge, United Kingdom. Histone antibodies were used at 1 μg/mL and nucleolin at 0.5 μg/mL. As for loading controls, blots were probed with actin (A5441, SigmaAldrich, 0.33 μg/mL) or tubulin (sc-5286, Santa Cruz Biotechnology Inc, Dallas, TX, 1 μg/mL) antibodies.
ELISA
Cell culture supernatants from mouse macrophages transfected with Dnm3os siRNAs (siDnm3os) or control siRNAs (siNTC) were centrifuged at 200g for 10 minutes to remove cell debris and stored frozen at -80°C until assayed using ELISA kits for the cytokines IL-6 (Cat. No. 550950, Lot no. 726959, BD Bioscience, La Jolla, CA) and TNF (tumor necrosis factor)-α (Cat. No. MTA00B, Lot No. P161075, Minneapolis, MN) according to the manufacturer's protocols. Results were expressed as pg/mL.
ChIP Assays
ChIP assays were performed as described. 28, 29 Briefly, RAW macrophages were crosslinked with 1% formaldehyde (Cat. No. F8775, Sigma-Aldrich) for 10 minutes at room temperature, quenched with 0.125 mol/L glycine for 5 minutes, and washed with ice-cold PBS. Cells were lysed in ChIP lysis buffer and chromatin was sheared (up to 200-600 bp) by sonication (8 cycles, 30 sec on / 30 sec off) using Bioruptor Pico (Diagenode, Denville, NJ). Immunoprecipitation was performed using 3 μg of antibodies specific to H3K9ac (Cat. Nos. ab10812, lot No. GR143846-2; Abcam, Cambridge, United Kingdom), or control rabbit IgG, overnight at 4°C. Immune complexes were collected onto 25 μL of magnetic protein G Dynabeads (Cat. No. 10003D, Novex, Waltham, MA) and washed. ChIP DNA was purified and dissolved in MilliQ water. ChIP assays for TF p65 (NF-κB) were performed using nuclear lysates prepared from crosslinked RAW macrophages. 30 Cells were lysed in cold lysis buffer 1 (140 mmol/L NaCl, 1 mmol/L EDTA, 50 mmol/L HEPES pH 7.5, 10% glycerol, 0.5% NP40, 0.25% Triton-x-100, 1x protease inhibitor) for 10 minutes at 4°C. Lysates were centrifuged at 2000 rpm for 5 minutes and the nuclear pellet was resuspended in lysis buffer 2 (10 mmol/L Tris pH 8.0, 200 mmol/L NaCl, 1 mmol/L EDTA, 0.5 mmol/L EDTA, 0.5 mmol/L EGTA, and 1x protease inhibitor), incubated for 10 minutes at 4°C and centrifuged at 2000 rpm for 5 minutes. The chromatin pellet was resuspended in ChIP lysis buffer, sonicated and ChIP assays were performed using 5 μg of p65 specific antibody (F-6 antibody, Cat. Nos. Sc-8008x, lot No. A1817; Santa Cruz Biotechnology, Inc. Dallas, TX). ChIP DNA in technical triplicates was analyzed by qPCR using SYBR Green reagent on the 7500 Fast Real-Time PCR system using ChIP-qPCR primers (Table II in the online-only Data Supplement). ChIP enrichment relative to input (% input) was calculated using the formula 2
.
RNA Fluorescence In Situ Hybridization to Determine Subcellular Localization of Dnm3os
RAW macrophages and indicated BMDMs were plated on coverslips and RNA fluorescence in situ hybridization was performed using 5′-end labeled (FAM) LNA oligonucleotide probes targeting Dnm3os (Sequence-attggacgagagcgatctgtga, Exiqon, Valencia, CA). Hybridization was performed as described. 31 Cells were blocked by incubating in prehybridization buffer (3% bovine serum albumin and 
Dnm3os RNA Pull-Down and Mass Spectrometry Analysis
RNA pull-down was performed as described before with some modifications. 32 Briefly, full-length Dnm3os sense and antisense strands were Biotin-labeled by in vitro transcription using Biotin RNA labeling Mix (Cat No. 11685597910, Roche) and T7 RNA Polymerase (Cat No. EP011, Stratagene). Biotinylated Dnm3os sense and antisense RNAs were treated with RNase-free DNase I and purified on G-50 Sephadex Quick Spin columns (Cat No. 11274015001, Roche). Biotinylation efficiency for sense and antisense strands were determined by Biotin Chromogenic Detection Kit (Cat No. K0661, Thermo Scientific). Biotinylated RNA (1 μg) was denatured by heating to 60°C for 10 minutes and slow-cooled to 4°C. RNA was mixed with 1 mg of nuclear extract prepared from PMs (for mass spectrometry) and RAW macrophages (for Western blot validations) in RNA immunoprecipitation buffer (150 mmol/L Kcl, 25 mmol/L Tris pH 7.4, 0.5 mmol/L DTT, 0.5% NP40, 100 mmol/L PMSF, and 1x protease inhibitor) and incubated at 4°C for 2 hours. Then, 60 μL of Streptavidin agarose beads (Cat No. SA10004, Invitrogen) were added to each binding reaction and further incubated at 4°C for 2 hours. Beads were quickly washed 5× in Handee spin columns (Cat No. 69725 Pierce, Thermo Fisher Scientific). Proteins were eluted using SDS buffer, separated on a 4% to 15% precast SDS gel (Cat No. 5671084, Criterion, Biorad, Hercules, CA) and stained with SimplyBlue SafeStain (Cat No. LC6065, Life Technologies). Bands were excised and subjected to protein identification by City of Hope's Mass Spectrometry Core. In some experiments, eluted proteins were also analyzed by Western blotting with indicated antibodies.
Gel-separated proteins were reduced with DTT (Cat No. R0861, Thermo Fisher Scientific), alkylated with iodoacetamide (Cat No. A3221-10VL, Sigma-Aldrich), and digested with a mixture of trypsin and LysC (Promega, Madison, WI). Peptides were extracted from the gel, evaporated to dryness in a vacuum centrifuge, and resuspended in 0.1% formic acid. Digested peptides were analyzed by LC/MS using an Orbitrap Fusion Mass Spectrometer with an EasyNano1000 nanoflow UHPLC (both Thermo Fisher Scientific). Peptides were loaded onto a 75 µm×2 cm PepMap trapping column packed with 3 µm C 18 silica particles, 100 Å pore size, then eluted through a 75 µm×25 cm PepMap analytical column packed with 2 µm C 18 silica particles, 100 Å pore size (both Thermo Fisher Scientific) using a 85-minute linear buffer A/B gradient from 8% to 25% buffer B (buffer A: 0.1% aqueous formic acid, buffer B: 0.1% formic acid in acetonitrile). MS Spectra of the intact peptides were acquired in the Orbitrap, and CID MS/MS spectra were acquired in the ion trap. Data were searched using Sequest in Proteome Discoverer 2.1 (Thermo Fisher Scientific). The database used was a concatenation of the Mus musculus RefSeq proteome and a database of common laboratory contaminant proteins and was searched separately in the forward (target) and reverse (decoy) direction. The search assumed tryptic specificity with a maximum of 2 missed cleavages, a precursor ion tolerance of 5 ppm, and a fragment ion tolerance of 0.6 Da. It assumed quantitative carbamidomethylation of cysteine and potential oxidation of methionine and acetylation of the protein amino terminus. Search results were loaded into Scaffold version 4.8.4 for probability assignment.
RNA-Seq and Ribosome Profiling Data Analysis
RNA-seq was performed at City of Hope's Integrative Genomics Core on HiSeq 2500 platform (Illumina, San Diego, CA). Raw sequences (Table I in the online-only Data Supplement) were aligned to the mouse reference genome mm9 using TopHat v2.0, 33 and the expression levels of RefSeq genes were counted using customized R scripts. The counts were normalized by trimmed mean of M value method and differentially expressed genes between groups were identified using Bioconductor package edgeR (fold change >1.5 and P<0.01). 34 Additionally, DESeq2 package 35 was used to normalize counts and identify differentially expressed genes (log2 fold change ≥0.5 and Padj <0.1). Differential genes identified using both methods were used to determine significantly modulated gene ontology and pathways using DAVID online annotation tools 36 and gene set enrichment analysis. 37 Enriched gene sets were represented in a bubble plot using plotly package in R. Briefly, expression values (transcripts per million [TPM]) in RAW-EV and RAW-Dnm3os (overexpressed) data sets were calculated for genes in enriched gene sets and used to make the bubble plot with the size of the bubble representing the number of genes. Log2 fold change and -log 10 P values of each gene were used to make a volcano plot using R scripts and differentially regulated genes are shown in green. Circos plot was generated using Circos software 38 with differentially regulated genes represented on mm9 chromosomes with links drawn from Dnm3os genomic location to the other genes. Only genes identified in the enriched gene sets from gene set enrichment analysis are shown on the Circos plot. Motif analysis of differentially expressed gene promoters was performed using TRAP (http://trap.molgen.mpg.de/cgi-bin/home.cgi). 39 Ribosome profiling data (GSE100739) and corresponding RNAseq data (GSE100873) were downloaded from Gene Expression Omnibus database. Sequences were aligned to mm9 as above using TopHat, and expression levels were expressed as TPM. Ribosomal occupancy was calculated for selected RNA and expressed as the ratio of ribosomal profiling TPM to input RNA-seq TPM as described.
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Data Deposition
RNAseq data is deposited in the Gene Expression Omnibus database (accession number GSE107557).
Statistical Analysis
Values are expressed as mean+SEM. GraphPad Prism 7.02 software (GraphPad Prism Software Inc, San Diego, CA) was used for statistical analyses. Normal distribution of each sample group was confirmed by Shapiro-Wilk normality test before comparing groups. For statistical comparison of 2 groups, unpaired 2-tailed Student t test was used. For the comparison of 3 or more groups with similar variances, 1-way ANOVA followed by Tukey or Dunnett post hoc tests were used. P values <0.05 were considered statistically significant for all tests used.
Results
Macrophage Dnm3os Is Upregulated in Diabetes Mellitus
We previously reported that several lncRNAs were differentially expressed in BMDMs from T2D db/db mice compared with control nondiabetic db/+ mice, but the function of only one of them (E330013P06) was determined. 24 Here, we investigated the regulation and functional role of another lncRNA Dnm3os, which was highly upregulated in BMDMs from db/db mice compared with db/+ ( Figure 1A ). Dnm3os is expressed as a 7.928 kb long transcript containing a single exon on mouse chromosome 1 from the opposite strand of a coding gene dynamin 3 (Dnm3), and its function in macrophages is unknown. To investigate Dnm3os functions, we first validated its upregulation using real-time quantitative PCR (RT-qPCR) in BMDMs from db/db macrophages compared with the control db/+ ( Figure 1B) . However, levels of the coding gene (Dnm3) on the opposite strand were not altered (results not shown). Next, we examined Dnm3os expression in other mouse models of metabolic syndrome and diabetes mellitus. Results showed that Dnm3os expression is also increased in PMs from high-fat diet-induced insulin-resistant mice versus normal chow diet fed mice ( Figure 1C) , PMs from STZ-induced type 1 diabetic mice ( Figure 1D ), and BMDMs from STZ-induced diabetic ApoE −/− mice ( Figure 1E ) that depict accelerated atherosclerosis 41 versus respective controls. Thus, Dnm3os upregulation may play a role in macrophage dysfunction associated with diabetes mellitus, insulin resistance, and macrovascular complications. A human ortholog, DNM3OS is also located on human chromosome 1 and shares 83% homology with mouse Dnm3os. We found that DNM3OS expression is significantly increased in CD14 + monocytes from T2D patients versus healthy controls ( Figure 1F ) demonstrating human disease relevance.
Nuclear Localization and Chromatin Enrichment of Dnm3os
Because lncRNA functions are dependent on subcellular localization, 15 we first examined Dnm3os levels in nuclear and cytoplasmic fractions in mouse RAW 264.7 macrophages. Results showed that Dnm3os is highly enriched in nuclear fractions compared with cytoplasmic ( Figure 1G ). Nuclear RNAs U6 snRNA and Neat1 served as controls ( Figure 1H and 1I). As nuclear lncRNAs may interact with chromatin to regulate gene transcription, we examined Dnm3os levels in chromatin and SNE from RAW macrophages. Results showed that Dnm3os is enriched by 2-fold in the chromatin fraction compared with SNE ( Figure 1J ). The known chromatinassociated lncRNA Kcnq10t1 26 served as positive control ( Figure 1K ). Ppia (loading control) showed similar Ct values in both chromatin and SNE fractions ( Figure 1L ). RNA fluorescence in situ hybridization further confirmed nuclear localization of Dnm3os and also showed that its levels increased in RAW cells treated with PA (200 μmol/L, 24 hours), a free fatty acid elevated in diabetes mellitus ( Figure 1M ). Furthermore, Dnm3os was also localized in the nucleus in BMDMs from db/db and db/+ mice and its signal was clearly increased in db/db BMDMs versus db/+ cells ( Figure 1N ). Similar nuclear enrichment and PA-mediated upregulation were also observed in National Institutes of Health 3T3 fibroblasts ( Figure I in the online-only Data Supplement). These results suggest that Dnm3os may have nuclear functions to modulate gene expression in macrophages.
Dnm3os Is Regulated by NF-κB Under Diabetic Conditions
We next examined the mechanism of Dnm3os upregulation under diabetic conditions using BMDMs treated with PA, normal glucose and HG. Dnm3os was significantly induced by PA with peak expression at 3 hours compared with control ( Figure 2A) , and by HG at 24 hours in BMDMs ( Figure 2B ). Moreover, PA also induced DNM3OS in human THP1 derived macrophages as well as in human primary CD14 + monocytederived macrophages from multiple donors ( Figure 2C and  2D) , confirming similar regulation in human macrophages. To investigate TFs regulating Dnm3os expression, we used TRANSFAC and Consite databases 42 to identify putative promoter TF binding sites. Results revealed an NF-κB binding site at −490 to −481 bp upstream of Dnm3os transcription start site. To verify the role of NF-κB, we generated 2 reporter constructs by cloning wild-type Dnm3os promoter (−1000 to + monocytes from control (Ctrl) and T2D patients. Gene expression normalized to reference gene is expressed as fold over control. Mean+SEM; n=12 to 14 (for B), n=6 (for C), n=8 (for D), n=5 (for E and F), *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001, unpaired 2-tailed t tests. The numbers above bar graphs represent ∆Ct values (Dnm3os-reference gene). G-I, RT-qPCR analysis of indicated RNAs from total, nuclear, and cytoplasmic (Cyto) fractions. U6 and Neat1 RNA were used as positive controls for nuclear RNAs. Gene expression normalized to Ppia is expressed as fold over total. Mean+SEM; n=3. *P<0.05; **P<0.01; ****P<0.0001, unpaired 2-tailed t tests. J, K, Relative abundance of indicated RNAs in chromatin (Chr) and soluble nuclear extracts (SNE) after normalization with Ppia transcript (L). Mean+SEM; n=3. **P<0.01, unpaired 2-tailed t tests. M, N, RNA fluorescence in situ hybridization (RNA-FISH) analysis of Dnm3os (green spots) in macrophages. M, Control and palmitic acid (PA; 200 μmol/L) treated RAW macrophages; (N) db/+ and db/db macrophages. Blue color nuclear staining with DAPI. Scale bars: 10 μm (M) and 7 μm (N).
+ 251 bp) and a mutant promoter (−480 to +251 bp) lacking the NF-κB site, upstream of firefly luciferase reporter gene ( Figure 2E through 2G) . Transient transfection of these constructs into RAW macrophages and luciferase assays showed that PA and HG increased the transcriptional activity of Dnm3os wild-type promoter, which was abrogated in NF-κB deletion mutant ( Figure 2H and 2I ). In addition, cotransfection with p65 (NF-κB active subunit) expression vector transactivated Dnm3os wild-type but not a mutant promoter in RAW macrophages ( Figure 2J ). Furthermore, ChIP assays with p65 antibody showed that PA treatment significantly increased p65 enrichment at the Dnm3os promoter compared with control in RAW macrophages ( Figure 2K ). These data clearly demonstrate that Dnm3os is upregulated by NF-κB binding to its promoter under diabetic conditions.
Dnm3os Overexpression Promotes Proinflammatory Functions in Macrophages
Next, we examined the effect of Dnm3os overexpression in macrophages, mimicking its upregulation in diabetes mellitus. We cloned full-length Dnm3os into pcDNA3.1 expression vector ( Figure II in the online-only Data Supplement) and generated RAW cell lines stably transfected with Dnm3os expression vector (RAW-Dnm3os) and empty pcDNA3.1 vector (RAW-EV). We then performed RNA-seq analysis in biological replicates using RNA extracted from these 2 cell lines ( Figure III in the online-only Data Supplement). Correlation and principal component analysis showed good correlation between the replicates ( Figure IVA and IVB in the online-only Data Supplement). Two hundred three genes were upregulated and 113 downregulated in Dnm3os overexpressing macrophages (RAW-Dnm3os) versus control RAW-EV (FDR <0.1, log2 fold change ≥0.5; Figure 3A ; Figure IVC in the online-only Data Supplement). DAVID analysis of Dnm3os-induced genes showed enrichment of key macrophage phenotypes including phagocytosis, inflammation, immune response, cell activation, chemotaxis, and response to wounding ( Figure 3B ). Furthermore, gene set enrichment analysis 37 showed enrichment of gene sets related to macrophage activation in genes upregulated by Dnm3os overexpression ( Figure 3C ). Using RT-qPCR we validated several key inflammatory genes upregulated by Dnm3os overexpression in RAW-Dnm3os versus RAW-EV ( Figure 3D through 3N) , although few upregulated genes tested could not be validated ( Figure V in the online-only Data Supplement). Interestingly, Dnm3os overexpression increased the expression of genes not only on chr1 on which it is located but also altered those present on other chromosomes ( Figure 3O ) suggesting both cis-and trans-actions. Furthermore, TF motif analysis showed enrichment of PU.1, NKx3-2, AP1, STAT, IRF1, REL binding sites in the promoters of upregulated genes ( Figure 3P through 3U), whereas EBF1, REST, and KLF4 sites were enriched in downregulated genes ( Figure 3V through 3X) . In addition, immunoblotting of cell lysates showed that Dnm3os overexpression increased global levels of permissive histone modifications such as H3K9ac and H3K27ac compared with 
RAW-EV (Figure VI in the online-only Data Supplement).
Together, these data suggest that overexpression of Dnm3os augments proinflammatory genes possibly via changes in epigenetic histone modifications in macrophages.
Dnm3os Enhances Inflammation and Phagocytosis
To further examine the function of Dnm3os and its target genes under diabetic conditions in vitro, we treated RAW-Dnm3os and RAW-EV macrophages with or without PA. Dnm3os was significantly increased by PA in both cell lines ( Figure 4A) along with several inflammatory genes ( Figure 4B through  4E) . Furthermore, PA-induced expression of Il6, Tnf, Nos2, and Cd36 was significantly greater in RAW-Dnm3os macrophages (pDnm3os) relative to RAW-EV ( Figure 4B through 4E), demonstrating that Dnm3os can further augment the proinflammatory effects of PA. Because lncRNAs can regulate nearby genes (cis-effects), we also tested if Dnm3os overexpression affects its nearby genes Mettl13 and Vamp4. However, both these genes were not affected ( Figure VII in the online-only Data Supplement). , and RAW-Dnm3os (pDnm3os) vs RAW-EV (EV) macrophages (P). Phagocytosis assays were performed in 96 wells and fluorescence of internalized particles measured on a plate reader. Mean+SEM; *P<0.05; n=4, unpaired 2-tailed t tests. Q, R, Phagocytosis assays were performed in BMDMs from db/+ and db/db mice without transfection (Q) or after transfection with siNTC (in db/+ and db/db) or siDnm3os (db/ db) BMDMs (R) mean+SEM; *P<0.05; n=5 to 6. S-X, Gene expression (S-X) and phagocytosis (Y) in THP1 macrophages after DNM3OS knockdown using GapmeR (gDNM3OS) vs control GapmeR (gCtrl). Mean+SEM, *P<0.05, unpaired t test (n=6-9 for S-X and 9-10 for Y).
Next, we examined if Dnm3os knockdown can inhibit candidate genes that were found to be upregulated in Dnm3os overexpressing cells. Dnm3os knockdown was confirmed in RAW macrophages transfected with Dnm3os siRNA (siDnm3os) relative to nontargeting control siNTC ( Figure VIIIA in the online-only Data Supplement). Furthermore, Dnm3os knockdown also significantly downregulated key inflammatory genes Il6 and Itgax (but not NFkbiz; Figure VIIIB through VIIID in the online-only Data Supplement) that were upregulated by Dnm3os. To examine direct relevance in diabetic macrophages, we next examined whether siRNA-mediated Dnm3os knockdown has similar effects in BMDMs from diabetic db/db mice, which exhibit enhanced expression of Dnm3os and proinflammatory genes in culture (ex vivo) relative to BMDMs from nondiabetic db/+ mice. We transfected db/db BMDMs with siNTC or siDnm3os and, as control, db/+BMDMs with siNTC oligonucleotides. siDnm3os significantly downregulated the increased expression of Dnm3os in BMDMs from db/db mice ( Figure 4F ) and, in parallel, also suppressed diabetes mellitus-induced enhanced inflammatory gene expression ( Figure 4G through 4I) and cytokine secretion ( Figure 4K and 4L) relative to siNTC transfected control db/+BMDMs. However, siDnm3os did not affect changes in Nfkbiz (Figure 4J ) or the host gene Dnm3 ( Figure IXA in the online-only Data Supplement). We also verified that the siRNA can target nuclear Dnm3os because siDnm3os significantly downregulated Dnm3os expression in nuclear fractions from db/db BMDMs versus siNTC transfected cells, but not in the cytoplasmic fractions where Dnm3os expression is much lower (Figure IXB through IXC in the online-only Data Supplement). Together, these results support a role for Dnm3os in diabetes mellitus-induced enhanced inflammatory phenotype of macrophages.
We next examined whether Dnm3os regulates phagocytosis, an important function of macrophages, by incubating fluorescently labeled E. coli bioparticles with macrophages after Dnm3os knockdown or overexpression. siDnm3os significantly inhibited phagocytosis compared with siNTC in BMDMs from control C57BL6 mice ( Figure 4M and 4N) . In contrast, Dnm3os overexpression in BMDMs (via transient transfection), and RAW-Dnm3os macrophages significantly increased phagocytosis relative to EV (Figure 4O and 4P) . Moreover, BMDMs from db/db mice exhibited increased phagocytosis relative to db/+ ( Figure 4Q ) that was attenuated by siDnm3os ( Figure 4R ). Interestingly, GapmeR-mediated human DNM3OS knockdown also significantly reduced inflammatory genes and phagocytosis in THP1 macrophages, suggesting similar mechanisms in human cells ( Figure 4S  through 4Y ). These results demonstrate that Dnm3os promotes inflammation and phagocytosis in macrophages.
Dnm3os Interacts With Nuclear Proteins in Macrophages
Interaction with key nuclear proteins is a major mechanism by which lncRNAs regulate gene expression. 11 Therefore, to gain additional insights into the mechanisms of Dnm3os actions, RNA pull-down assays 43 were performed to identify interacting protein partners of Dnm3os. Dnm3os sense and antisense (negative control) transcripts were biotinylated by in vitro transcription and RNA integrity as well as biotinylation efficiency of probes verified by denaturing gel electrophoresis and dot blot assays, respectively (Figure X in the online-only Data Supplement). Nuclear extracts from normal mouse PMs were incubated with these 2 biotinylated probes and RNAprotein complexes resolved on an SDS-PAGE gel ( Figure 5A ). Parallel protein bands in different regions of the gel from sense and antisense lanes were subjected to mass spectrometry analysis. Results showed that several nuclear proteins were specifically associated with Dnm3os-sense strand, but not with antisense ( Figure 5B ). These included nucleolin, ILF-2, actinrelated protein 3, RNA-binding protein Ralv short isoform, heterogeneous nuclear ribonucleoproteins U like protein 2, and heterogeneous ribonucleoprotein A1 isoform. To validate these interactions, RNA-protein complexes from RNA-pull down assays were immunoblotted with antibodies to nucleolin and ILF-2. Results showed that both proteins interacted specifically with sense Dnm3os RNA but not antisense RNA ( Figure 5C and 5D) . Furthermore, RNA fluorescence in situ hybridization with Dnm3os probe coupled with immunofluorescence using specific antibodies also showed the nuclear colocalization of Dnm3os with nucleolin and ILF-2 in both control and PA-treated macrophages ( Figure 5E and 5F). These results clearly demonstrate that Dnm3os interacts with nucleolin and ILF-2 in macrophages.
Nucleolin Modulates Proinflammatory and Epigenetic Actions of Dnm3os in Macrophages
Nucleolin is a multifunctional nucleolar protein 44 and one of its key functions includes regulation of chromatin structure. But its function in macrophages in diabetes mellitus is unknown. Recent studies suggested an atheroprotective function in macrophages 45 and anti-inflammatory effects in HeLa cells. 46 Therefore, we hypothesized that nucleolin may negatively regulate proinflammatory functions of Dnm3os and that inhibition of such interactions under diabetic conditions may promote inflammatory gene regulation. To test this, we checked nucleolin protein levels under diabetic conditions. PA and HG plus PA treatment significantly decreased nucleolin protein levels in RAW macrophages compared with the normal glucose-treated cells ( Figure 6A and 6B). We also found that nucleolin protein levels were significantly reduced in BMDMs from diabetic db/db mice relative to control db/+ ( Figure 6C and 6D) . This supports the notion that inhibition of nucleolin under diabetic conditions in vivo might promote inflammatory gene expression.
Next, we examined the effect of nucleolin knockdown on inflammatory gene expression in Dnm3os overexpressing macrophages. Transfection with nucleolin siRNA (siNcl) significantly inhibited nucleolin mRNA and protein versus siNTC in both RAW-Dnm3os and RAW-EV macrophages ( Figure 6E through 6G). Furthermore, nucleolin knockdown increased the expression of proinflammatory gene Il6 in RAW-EV macrophages and this effect was further significantly enhanced in RAW-Dnm3os macrophages ( Figure 6H ).
Next, we tested whether Dnm3os has trans-effects on inflammatory genes by augmenting permissive chromatin modifications like H3K9ac at their promoters. We examined the role of such epigenetic mechanisms in Il6 regulation by Dnm3os-nucleolin interactions using ChIP assays with H3K9ac antibody and qPCR with primers specific to Il6 promoter ( Figure 6I ). Interestingly, nucleolin depletion (siNcl) increased the enrichment of H3K9ac at Il6 promoter in control RAW-EV macrophages relative to siNTC ( Figure 6J ).
Moreover, Dnm3os overexpression also increased H3K9ac at the Il6 promoter in RAW-Dnm3os macrophages and notably, this effect was further enhanced by nucleolin depletion ( Figure 6J ). However, nucleolin knockdown did not alter H3K9ac at Tnf and Nos2 promoters ( Figure XI in the online-only Data Supplement). It is possible that other active chromatin marks beside H3K9ac may be involved in Dnm3os-mediated increases in other target inflammatory genes besides Il6. Thus, Dnm3os-nucleolin interactions can regulate, in part, the macrophage inflammatory phenotype via epigenetic mechanisms such as increased permissive histone modifications and chromatin relaxation.
Discussion
In this study, we demonstrate a novel mechanism of enhanced macrophage inflammatory phenotype in diabetes mellitus by lncRNA Dnm3os. Macrophages are key players in promoting inflammation implicated in insulin resistance, lipid accumulation in the vessel wall, and related vascular complications. Furthermore, increased oxidative stress in diabetes mellitus increases formation of oxidized LDL (low-density lipoprotein), which further enhances inflammation. Concerted actions of all these events play important roles in the initiation and progression of atherosclerosis. 3 Multiple signaling and epigenetic mechanisms have been implicated in augmenting these processes under diabetic states. Notably, lncRNAs have been recently discovered to play a role in macrophage inflammation under normal and diabetic conditions. 20, 24 Here, we showed that the expression of lncRNA Dnm3os is increased in macrophages derived from several mouse models of metabolic disorders including type 1 diabetic, T2D, obesity, and insulin resistance. Dnm3os expression was upregulated in BMDMs from both male (Figure 1 ) and female db/db mice ( Figure XII in the online-only Data Supplement). Moreover, Dnm3os is also upregulated in STZinjected Apoe −/− mice, a model of diabetes mellitus-induced accelerated atherosclerosis 41 indicating its association with diabetic vascular diseases. We confirmed that Dnm3os lacks coding potential using PhyloCSF, CPAT, and macrophage ribosome profiling databases, and in vitro transcription/ translation assays (Figure XIIIA through XIIIC in the onlineonly Data Supplement). Moreover, Dnm3os is conserved in humans and expressed in multiple tissues including adipose, aorta, and whole blood ( Figure XIV in the online-only Data Supplement). Interestingly, we found that Dnm3os is also upregulated in monocytes from T2D patients. These in vivo findings suggest that Dnm3os is regulated by hyperglycemia and hyperlipidemia in diabetes mellitus. Accordingly, our in vitro experiments clearly demonstrated that HG as well as PA, a free fatty acid abundant in obesity and T2D, increased Dnm3os expression in macrophages.
Reports show that Dnm3os is regulated by Twist and PPAR-α (peroxisome proliferator-activated receptor-alpha) in cardiac and endothelial cells. 47, 48 Our studies show that HG and PA activate the Dnm3os promoter via NF-κB. PA can increase inflammatory gene expression via TLR4 (Tolllike receptor 4) activation, and HG can via activation of tyrosine kinases and protein kinase C. Both stimuli also activate NF-κB TF to induce inflammatory genes. Our results using macrophages derived from diabetic db/db mice support a role for Dnm3os in mediating diabetes mellitus-induced proinflammatory phenotype. Previous studies showed activation of NF-κB in this ex vivo model of diabetes mellitus-induced accelerated inflammation and macrophage activation. 4 Thus, activation of NF-κB by several factors in obesity and diabetes mellitus can increase Dnm3os in macrophages to further augment macrophage dysfunction. However, NF-κB activation in diabetes mellitus can clearly have effects on multiple inflammatory pathways and, whether Dnm3os mediates some or many of these effects in vivo has to be determined.
Mechanistically, lncRNAs regulate gene expression via distinct processes that promote or inhibit recruitment of transcription and epigenetic regulators to modulate chromatin structure. 15 In macrophages, lncRNAs THRIL, EPS, and lncRNA-COX-2 interact with RNA-binding proteins of hnRNP family to regulate NF-κB function and dysregulate chromatin structure around inflammatory genes. 20 We found that Dnm3os is highly enriched in the nucleus and associated with chromatin, supporting its role in gene regulation. We also observed Dnm3os interacts with nucleolin, ILF-2, and several RNA-binding proteins including hnRNPs. Interaction of hnRNPs with lncRNAs has been widely demonstrated in macrophages. 20 ILF-2 regulates IL2 expression in T-cells, but its function in other cell types is unclear. 49 Nucleolin, a 77 kDa protein highly enriched in the nucleolus, has multiple functions especially in chromatin structure and transcription. 44 However, nucleolin function in diabetes mellitus and lncRNA-mediated gene regulation has not been previously examined. Our new results demonstrate that Dnm3os-nucleolin interaction could be a key mechanism regulating inflammatory phenotype of macrophages. We found that nucleolin inhibited Il6 gene expression which suggests antiinflammatory functions. Moreover, Dnm3os-induced Il6 gene expression was further enhanced after nucleolin knockdown in macrophages. In support of our data, studies in HeLa cells showed nucleolin downregulation increased IL6 expression, 46 whereas in macrophages, nucleolin overexpression inhibited oxidized-LDL-induced foam cell formation through enhancing ABCA1 (ATP-binding cassette sub family A member 1) expression. 45 Further investigation is needed to determine whether Dnm3os can modulate macrophage foam cell formation through interactions with nucleolin. Our studies suggest that nucleolin-Dnm3os interaction inhibits inflammatory genes possibly via promoting repressive chromatin structure. Because diabetic conditions increase Dnm3os and decrease nucleolin levels, consequently, this can promote permissive histone modifications such as H3K9ac and open chromatin formation at inflammatory genes. Nucleolin functions are regulated by multiple posttranslational modifications including phosphorylation and acetylation, which could affect its protein stability. 44, 50 Further studies are needed to examine how such complex regulatory mechanisms are involved in the downregulation of nucleolin by HG and PA.
We also observed Dnm3os increases phagocytosis in macrophages. It is possible Dnm3os enhances phagocytosis via upregulation of Cd36 ( Figure 4E ), a key regulator of phagocytosis and foam cell formation. 51 The role of phagocytosis in atherosclerosis is quite complex. Increased phagocytosis promotes excess uptake of oxidized lipids and foam cell formation, key steps in the initiation of lesions. Furthermore, in advanced complex lesions, nonspecific increases in phagocytosis of apoptotic cells could affect plaque stability. 52 Thus, macrophage Dnm3os upregulation in diabetes mellitus may affect initiation and progression of vascular disease. However, further in vivo studies are needed to determine whether Dnm3os also plays a role in clearance of pathogens and apoptotic cells, important events in infection and atherosclerosis, respectively.
Previous studies in cardiac and endothelial cells showed a role for Dnm3os during heart failure and hypertension, 47, 48 but they examined its function as a host gene for miR-199 and miR-214, and not as a lncRNA. In our study, overexpression of miR-199a and miR-214 did not affect most of the tested Dnm3os target genes ( Figure XV in the online-only Data Supplement), suggesting mostly miRNA-independent effects for Dnm3os in diabetic macrophages. Other studies have also shown similar lncRNA functions of miRNA host genes in different cell types . 24, 53 Taken together, our results demonstrate lncRNA Dnm3os-mediated novel mechanisms for increased macrophage inflammatory gene expression in diabetes mellitus. Under normal conditions, nucleolin interacts with and prevents the functional ability of Dnm3os to increase enrichment of permissive histone modifications like H3K9ac at promoters of inflammatory genes such as Il6. But, under diabetic conditions, increased Dnm3os and reduced nucleolin levels disrupt such interactions, allowing Dnm3os to enhance promoter H3K9ac, likely via recruitment of histone acetyltransferases, thereby leading to chromatin relaxation, upregulation of target inflammatory, and macrophage dysfunction ( Figure  XVI in the online-only Data Supplement). As certain human macrophage lncRNAs have also recently been associated with cardiometabolic disorders, 54 increased understanding of macrophage lncRNAs and their interacting proteins could aid the development of better therapies for inflammatory diabetic complications.
Sources of Funding
This study was supported by grants from the National Institutes of Health (NIH), R01 DK065073, R01 HL106089, and R01 DK081705 (to R. Natarajan). Research reported in this publication included work performed in the following Campus Cores: Integrative Genomics, DNA/RNA synthesis, and Mass Spectrometry and Proteomics (supported by the National Cancer Institute of the NIH under award number P30CA33572), and The Light Microscopy Core.
Disclosures
None.
